Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_assertion type Assertion NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_head.
- NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_assertion description "[Moreover, PRL-3 overexpression was significantly associated with tumor stage (OR = 2.25; 95% CI = 1.63-3.12; P<0.001), depth of invasion (OR = 2.03; 95% CI = 1.38-2.98; P<0.001), vascular invasion (OR = 2.52; 95% CI = 1.79-3.56; P<0.001), lymphatic invasion (OR = 3.74; 95% CI = 2.49-5.63; P<0.001), and lymph node metastasis (OR = 4.56; 95% CI = 2.37-8.76; P<0.001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_provenance.
- NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_assertion evidence source_evidence_literature NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_provenance.
- NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_assertion SIO_000772 24204707 NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_provenance.
- NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_assertion wasDerivedFrom befree-20150227 NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_provenance.
- NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_assertion wasGeneratedBy ECO_0000203 NP854885.RAPS3GrZb2sT-WzjxOQrsSK0L5xY19rE_DXKCl9O1eYfw130_provenance.